Biomaterial Database

Studies on Japanese-produced chick embryo cell culture rabies vaccines. 1991

Y T Arai, and T Ogata, and A Oya

National Institute of Health, Tokyo, Japan.

We studied the potency, antibody response, and side reactions of commercial Japanese chick embryo cell (CEC) rabies vaccines for humans. The CEC rabies vaccines had indexes of 10(5.1) and 10(6.0) in Habel tests, and have had potencies higher than those of the International Reference Vaccine II by National Institutes of Health (NIH) tests. Thirty healthy adults received 1 ml of the CEC rabies vaccines subcutaneously as primary immunization on days 0 and 7. Between six and 12 months after the primary immunization, 22 of the 30 subjects showed neutralizing antibody levels greater than or equal to 1:40 by the rapid fluorescent focus inhibition test (RFFIT). The 30 subjects had been given booster immunizations of the CEC rabies vaccines at 8-14 months in addition to the primary immunization. Six to 12 months after the booster immunizations, 27 of the 30 subjects showed antibody levels greater than or equal to 1:40. No severe side reactions were reported during the course of vaccination. Thus we conclude that CEC rabies vaccine is effective and safe for pre-exposure immunization.

UI	MeSH Term	Description	Entries
D007117	Immunization, Secondary	Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.	Immunization, Booster,Revaccination,Secondary Immunization,Booster Immunization,Booster Immunizations,Immunizations, Booster,Immunizations, Secondary,Revaccinations,Secondary Immunizations
D007564	Japan	A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo.	Bonin Islands
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D009500	Neutralization Tests	The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).	Neutralization Test,Test, Neutralization,Tests, Neutralization
D011819	Rabies Vaccines	Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis.	Rabies Human Diploid Cell Vaccine,Rabies Vaccine,Vaccine, Rabies,Vaccines, Rabies
D011820	Rabies virus	The type species of LYSSAVIRUS causing rabies in humans and other animals. Transmission is mostly by animal bites through saliva. The virus is neurotropic multiplying in neurons and myotubes of vertebrates.	Rabies viruses
D002478	Cells, Cultured	Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.	Cultured Cells,Cell, Cultured,Cultured Cell
D002642	Chick Embryo	The developmental entity of a fertilized chicken egg (ZYGOTE). The developmental process begins about 24 h before the egg is laid at the BLASTODISC, a small whitish spot on the surface of the EGG YOLK. After 21 days of incubation, the embryo is fully developed before hatching.	Embryo, Chick,Chick Embryos,Embryos, Chick
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man